Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-04-16

COORDINATION RESEARCH ON IMMUNOGENETICS OF AIDS

Obiettivo

The aim of this Concerted Action was to clarify whether immunogenetic markers of the major histocompatibility complex (MHC) of man, the HLA system, controls the susceptibility to become infected with HIV and/or the susceptibility to develop AIDS when infected.
The coordinated research programme is to investigate whether there is a genetic predisposition to become infected with human immunodeficiency virus (HIV) upon exposure to and/or to develop acquired immune deficiency syndrome (AIDS) once infected with HIV. 14 different groups from 12 different countries participate in this collaboration.
13 different groups from 12 European countries human leucocyte antigen (HLA ) typed and provided HLA data on 8614 unrelated controls and HLA and clinical data on 1581 unrelated patients including 1246 HIV infected ones. No differences in HLA marker frequencies were observed between 127 HIV positive and 148 HIV negative haemophiliacs indicating that the HLA system does probably not control infectability in this group of patients.
In other groups, there was some evidence that the susceptibility to become infected with HIV might be partly controlled by the HLA system. There was better evidence that HLA factors may influence the course of the HIV infection because significantly more antigens than should be expected showed significant differences in the frequencies when comparing patients with symptomatic HIV infection with patients without symptoms. Moreover, when comparing 114 patients classified as fast progressors with 145 classified as slow progressors, the HLA-B35 antigen was significantly associated with fast progression.
Apart from the HIV studies, this investigation also provided evidence against a previously claimed association between haemophilia and HLA-DR5.

The major goal of this CA was to clarify whether there are immunogenetic markers associated with a predisposition for HIV-infection and/or the subsequent development of AIDS. In order to answer this question, it was felt that various well-characterized cohorts from different homogeneous European populations together with ethnically matched controls were well suited for study, and the HLA system was considered the best candidate as a marker system because it has been shown to control the susceptibility to a variety of other diseases. Moreover, the HLA system is the most polymorphic genetic system with known function in man. The newly developed DNA-technology allowed definition of new markers not recognizable with conventional methods, but the distribution of these markers in the population had to be established. Moreover, training of staff in these new methods and some degree of standardization was required. To solve these problems, collaboration between a number of groups within the EEC and COST countries was required, which thus became one of the objectives of the study.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: Il Vocabolario Scientifico Europeo.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Programma(i)

Programmi di finanziamento pluriennali che definiscono le priorità dell’UE in materia di ricerca e innovazione.

Argomento(i)

Gli inviti a presentare proposte sono suddivisi per argomenti. Un argomento definisce un’area o un tema specifico per il quale i candidati possono presentare proposte. La descrizione di un argomento comprende il suo ambito specifico e l’impatto previsto del progetto finanziato.

Invito a presentare proposte

Procedura per invitare i candidati a presentare proposte di progetti, con l’obiettivo di ricevere finanziamenti dall’UE.

Dati non disponibili

Meccanismo di finanziamento

Meccanismo di finanziamento (o «Tipo di azione») all’interno di un programma con caratteristiche comuni. Specifica: l’ambito di ciò che viene finanziato; il tasso di rimborso; i criteri di valutazione specifici per qualificarsi per il finanziamento; l’uso di forme semplificate di costi come gli importi forfettari.

CON - Coordination of research actions

Coordinatore

University Hospital of Copenhagen (Rigshospitalet)
Contributo UE
Nessun dato
Indirizzo
Tagensvej 20
2200 Copenhagen N
Danimarca

Mostra sulla mappa

Costo totale

I costi totali sostenuti dall’organizzazione per partecipare al progetto, compresi i costi diretti e indiretti. Questo importo è un sottoinsieme del bilancio complessivo del progetto.

Nessun dato
Il mio fascicolo 0 0